With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Hims & Hers Health (NYSE:HIMS) shares plunged early Tuesday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Earnings per ...

Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...